Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Zonisamide for Weight Reduction in Obese Adults

This study has been completed.
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00275834
First received: January 10, 2006
Last updated: July 9, 2014
Last verified: February 2013
Results First Received: December 10, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Obesity
Intervention: Drug: Zonisamide

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo No text entered.
Zonisamide 200 mg No text entered.
Zonisamide 400 mg No text entered.
Total Total of all reporting groups

Baseline Measures
   Placebo   Zonisamide 200 mg   Zonisamide 400 mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 74   76   75   225 
Age 
[Units: Participants]
       
<=18 years   0   0   0   0 
Between 18 and 65 years   74   76   75   225 
>=65 years   0   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 43.5  (10.3)   44.2  (10.1)   42.3  (10.0)   43.4  (10.1) 
Gender 
[Units: Participants]
       
Female   44   45   45   134 
Male   30   31   30   91 
Region of Enrollment 
[Units: Participants]
       
United States   74   76   75   225 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Body Weight   [ Time Frame: 1 year ]

2.  Secondary:   Proportions of Patients With 5% Weight Loss   [ Time Frame: 1 year ]

3.  Secondary:   Proportions of Patients With 10% Weight Loss   [ Time Frame: 1 year ]

4.  Secondary:   Waist Circumference   [ Time Frame: 1 year ]

5.  Secondary:   Inflammatory Markers   [ Time Frame: 1 year ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Lipids   [ Time Frame: 1 year ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Quality of Life   [ Time Frame: 1 year ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

8.  Secondary:   Psychological Measures   [ Time Frame: 1 year ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

9.  Secondary:   Blood Pressure   [ Time Frame: 1 year ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information